Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mind Medicine Mindmed Inc (NQ: MNMD )

6.265 -0.075 (-1.18%)
Streaming Delayed Price Updated: 1:31 PM EDT, Oct 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mind Medicine Mindmed Inc

< Previous 1 2
...
25 26 27 28 29 30 31 32 Next >
Field Trip Health Heads To The Nasdaq As Wall Street Opens Up To "Psychedelics Renaissance"
Excitement around psychedelics grows as major U.S. exchanges make room for more companies in the sector. On Friday, 
Via Benzinga
Psychedelics Gain More Traction as New Research Aims to Address Chronic Pain and Mental Illness
Via FinancialNewsMedia
Topics Law Enforcement
Exposures Legal
Mind Medicine Has More Obstacles Than Opportunities
MNMD stock could revolutionize mental healthcare with its novel therapeutics, but there are currently too many risks with its business. 
Via InvestorPlace
Psychedelic Decriminalization Creating Market Opportunities
Via FinancialNewsMedia
Topics Cannabis Law Enforcement
Exposures Cannabis Legal
Psyched: Numinus, MindMed, Cybin Reach Milestones, Harvard To Study Psychedelics Law, Michael Pollan Dives Into Mescaline
Michael Pollan’s New Book Takes A Deep Dive Into Mescaline – Will This Be A Turning Point For The Recognition And Study of&n... 
Via Benzinga
How To Invest In "Magic Mushrooms" (Psychedelics)
A look at psychedelics as stock market investment opportunities and identifying alternative strategies on how to invest. 
Via Talk Markets
MindMed Stock Is Overvalued and Too Risky to Own
MindMed can be the future of psychedelic medicines, but without cash flow from revenue, MNMD stock is nothing to get excited about. 
Via InvestorPlace
Psychedelics Research FYI: Every Clinical Trial Underway Right Now Involving Public And Private Companies
This article was made possible thanks to invaluable research by Michael Haichin and Josh Hardman from Ps... 
Via Benzinga
The 6 Leading Psychedelic Stocks In Drug R&D
Drug R&D in the emerging psychedelic drug industry continues to advance. Share prices continue to lag. Here's a comparison of the strengths and weaknesses of six of the leaders in psychedelic drug R&D... 
Via Talk Markets
Rising Prevalence of Mental Depression & Anxiety Major Drivers Propelling Demand In Psychedelic Drugs Market
Via FinancialNewsMedia
Psyched: GH Research Debuts on Nasdaq, Compass Reaches Psilocybin Research Milestone, Maxim Gives BUY Rating to 10 Psychedelics Companies
Irish 5-MeO-DMT Company GH Research Debuts On Nasdaq GH Research, a Dublin-based company studying the potential o... 
Via Benzinga
The MindMed Psychedelic Revolution Will Take Years to Come to Fruition
MNMD stock aspires to be a lot to many but could flop. Prices are low, risk is high and speculators could become savants. 
Via InvestorPlace
Maxim Group Gives Buy Rating To 10 Psychedelic Stocks: Compass, MindMed, Cybin, Field Trip And More
Institutional analysts are taking a liking to the industry ... 
Via Benzinga
Video: Talking Cannabis With Aurora Co-Founder Terry Booth | Benzinga Cannabis Insider 6/29
Benzinga’s 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Get a Dose of Innovative Science With Mind Medicine
MNMD stock ran high last year, but the story is still being written as Mind Medicine marks progress with its psychedelics-based treatments. 
Via InvestorPlace
Psychedelics-Focused MindMed Joins FTSE Russell 3000 Index, 'A True Honor'
A psychedelics-focused medicine company MindMed (NASDAQ: 
Via Benzinga
Pandemic Fallout: 6 Mental Health Stocks To Watch
One of the most devastating long-term impacts of the COVID-19 pandemic may be the toll it has taken on people’s mental health. The next globa... 
Via Benzinga
Exposures COVID-19
MindMed Can Play a Big Role in the Growing Mental Wellness Industry
With Covid-19 increasing the frequency of mental health problems, MNMD stock is a way to invest in psychedelics, which are seeing legitimacy. 
Via InvestorPlace
Exposures COVID-19
Why This MindMed Analyst Is Bullish: 'One Of The Most Diverse Pipelines In Psychedelics'
Mind Medicine (MindMed) Inc (NASDAQ:MNMD) shares traded hi... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 28, 2021
Upgrades For Toll Brothers Inc (NYSE: 
Via Benzinga
Cannabis Movers & Shakers: HempFusion, Decibel, ARCA, Love Hemp, MindMed, Halo
HempFusion Wellness Promotes VP And Controller Maria Leal To Interim CFO HempFusion Wellness Inc. (TSX: 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Atai IPO Day An Underwhelming Event
The IPO of atai Life Sciences was arguably the most-anticipated event in the emerging psychedelic drug industry. It failed to live up to expectations. 
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
Psyched: Atai Life Sciences Hits Nasdaq, Canada To Fund Ketamine Trials, Mydecine Launches AI Drug-Discovery Platform
Atai Life Sciences (NASDAQ: ATAI) made its highly-anticipated Nasdaq... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Peter Thiel-backed Psychedelics Company Rings Nasdaq Bell: Atai Life Sciences Goes Public
Atai Life Sciences (NASDAQ:ATAI), a biotech company in the... 
Via Benzinga
New Psychedelic Drug Stock To Debut After Upsized IPO Prices At High End
Atai Life Sciences, a backer of psychedelic-drug developers, will start trading Friday, after an upsized offering for the Atai IPO. 
Via Investor's Business Daily
Topics Initial Public Offering
Exposures Securities Market
Is Mind Medicine a Buy?
It offers a great way to tap into the psychedelics market -- but is it too risky of an investment right now? 
Via The Motley Fool
Topics Cannabis
Exposures Cannabis
Could Mind Medicine Be a Millionaire-Maker Stock?
Yes, but with the chance of great reward comes substantial risk. 
Via The Motley Fool
Recent Surge for Intellectual Property & Patents in Psychedelic Therapies & Drug Development
Via FinancialNewsMedia
Topics Intellectual Property
Exposures Intellectual Property
Psyched: Atai's $214M IPO, MindMed CEO Resigns, Field Trip Applies To Nasdaq, Cybin And Novamind Target Frontline Health Workers
Atai Launches $214 Million Nasdaq IPO Offering Psychedelics biotech platform Atai life Sciences has announced an initi... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Mind Medicine Stock Might Still Be Worth the Risk Here
The rampant addiction crisis in America requires a new effective solution, which may suit MNMD stock well. 
Via InvestorPlace
< Previous 1 2
...
25 26 27 28 29 30 31 32 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.